MENLO PARK, Calif., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Jim Schoeneck, will be presenting at the Stifel Nicolaus Healthcare Conference in Boston on Wednesday, Sept. 7. The presentation is scheduled for 8:35 am EDT.

The presentation will be webcast live and the webcast can be accessed via the investor relations page of the Depomed website at www.depomed.com. It can also be accessed directly via the following link: http://www.veracast.com/webcasts/stifel/healthcare2011/01102536.cfm

A recording of the webcast will be archived for up to 30 days on the company's website.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with one approved product on the market and another recently approved product. GRALISE™ (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. The company also has a robust pipeline including SERADA®, which is in Phase 3 clinical development for menopausal hot flashes, as well as earlier stage candidates. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for controlled release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

The Depomed, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7529

CONTACT: Abe Wischnia
         Director, Investor Relations
         650-462-5900